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HORMESIS, CELL DEATH, AND REGENERATIVE MEDICINE FOR NEURODE-
GENERATIVE DISEASES
Guanghu Wang  Institute of Molecular Medicine and Genetics, Medical
College of Georgia, Georgia Health Sciences University
 Although the adult human brain has a small number of neural stem cells, they are
insufficient to repair the damaged brain to achieve significant functional recovery for neu-
rodegenerative diseases and stroke. Stem cell therapy, by either enhancing endogenous
neurogenesis, or transplanting stem cells, has been regarded as a promising solution.
However, the harsh environment of the diseased brain posts a severe threat to the survival
and correct differentiation of those new stem cells. Hormesis (or preconditioning, stress
adaptation) is an adaptation mechanism by which cells or organisms are potentiated to
survive an otherwise lethal condition, such as the harsh oxidative stress in the stroke brain.
Stem cells treated by low levels of chemical, physical, or pharmacological stimuli have
been shown to survive better in the neurodegenerative brain. Thus combining hormesis
and stem cell therapy might improve the outcome for treatment of these diseases. In addi-
tion, since the cell death patterns and their underlying molecular mechanism may vary in
different neurodegenerative diseases, even in different progression stages of the same dis-
ease, it is essential to design a suitable and optimum hormetic strategy that is tailored to
the individual patient.
Keywards: hormesis, preconditioning, regenerative medicine, stem cells, cell death, apoptosis, necrosis,
autophagy, molecular chaperone, Hsp90 inhibitors.
INTRODUCTION
Regenerative medicine is an emerging field of treatments based on the
concept of producing new cells to replace malfunctioning or damaged
ones as a vehicle to treat disease and injury (Steindler 2007; Hess and
Borlongan 2008). It could aid in easing symptoms or even reverse disease
progression of diseases where pharmacological interventions and other
treatment modalities are no longer sufficient or not available (Gogel et al.
2011). This is especially true for diseases associated with aging such as neu-
rodegenerative diseases, type II diabetes, and heart failure (Haas et al.
2005; Chang et al. 2007; Caspi et al. 2007). This is also true for medical con-
ditions resulting from damage to cells due to acute disease, such as trau-
ma, infarction and burns (Li et al. 2008a; Chang et al. 2007).
Although stem or progenitor cells are presumed to survive various
stresses, the harsh insults from the diseased proteins, inflammatory
cytokines, and cytotoxic cells in the areas of tissue damage and regenera-
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tion may significantly hamper their viability, especially during the first few
days after transplantation (Norgaard et al. 2006; Bliss et al. 2006; Kelly et
al. 2004; Hicks et al. 2009).
A term initially used in toxicology, hormesis has been defined as a
dose-response relationship in which there is an inhibitory response at
higher doses but a stimulatory response at lower doses, resulting in a U-
shaped or inverted U-shaped dose response (Fig. 1) (Mattson 2008;
Calabrese et al. 2007; Kendig et al. 2010). When given at a small quantity,
a harmful substance gives rise to beneficial effects in living organisms. A
good examples is alcohol consumption, in which light drinking helps pre-
vent heart disease and stroke (Cook and Calabrese 2006). Other exam-
ples of hormesis include physical exercise, ischemia preconditioning, and
chemical treatment of cells (Calabrese et al. 2007; Mattson 2008;
Calabrese et al. 2008a; Wang et al. 2012; Wang et al. 2011).
Hormesis is believed to be a common paradigm throughout nature
and is the foundation of evolution (Calabrese et al. 2007; Norgaard et al.
2006; Rattan 2004; Mattson 2008). Over the years, life on earth has went
through harsh environment in which cells and organisms were often
exposed to adverse stresses, including free radicals and toxic substances.
Only those organisms that developed a complex mechanism to adapt to or
cope with the changing environment have survived (Mattson 2008).
Several studies have reported that a mild stress produces stress adaptation
in cells that potentiates them to endure a much severe condition (reduc-
tion of cell death) (Norgaard et al. 2006; Geraci et al. 2006; Kraft et al. 2006;
Madhavan et al. 2006; Mattson 2008; Kendig et al. 2010; Wang et al. 2011).
In this article, we will discuss the potential application of hormesis in
regenerative medicine for neurodegenerative diseases and stroke. Since
cell death/survival is crucial for regenerative medicine, and the cell
death patterns and their underlying molecular mechanism may vary in
Hormesis for Regenerative Medicine
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FIGURE 1. The U-shaped dose response curve of Hormesis. From Calabrese and Baldwin (Calabrese
and Baldwin 2001), used with permission. 
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different neurodegenerative diseases, even in different progression stages
of the same disease, it is essential to design a suitable and optimum
hormetic strategy that is tailored to the individual patient, we will first
briefly review the common cell death pathways related to neural
stem/progenitor cells, namely apoptosis, autophagy, and necrosis, which
could be potentially averted by hormesis.
CELL DEATH PATHWAYS
Apoptosis - the programmed cell death
Apoptosis is an important part of life for multicellular organisms (see
reviews (Lockshin and Zakeri 2004; Jin and El-Deiry 2005; Rufini and
Melino 2011)). It plays an essential role in development and homeostasis.
During early development of many organs, for example the brain and the
fingers, cells are produced in excess which eventually undergo apoptosis
and thereby contribute to organ and tissue morphogenesis. Features of
apoptosis include condensed nuclei, cell shrinkage, cell membrane bleb-
bing, and DNA fragmentation. Apoptotic cell death is considered to be a
major cell death pathway for transplanted stem cells, including neural
progenitor cells (NPCs), mesenchymal stem cells (MSCs), and bone mar-
row stem cells (BMSCs) (Theus et al. 2008; Wang et al. 2011; Geng 2003).
For example, It has been reported that only less than 1% of the injected
BMSCs survive past one week (Toma et al. 2002).
Apoptotic cell death is usually categorized into two distinct pathways:
caspase-dependent and caspase-independent (Jin and El-Deiry 2005;
Rufini and Melino 2011; Lockshin and Zakeri 2004) (Fig. 2). In the cas-
pase-dependent pathway, a series of specific cysteine proteases, named
caspases, are activated in a cascade of proteolytic maturation steps in
response to environmental or physiological cell death signals (Fig. 3)
(Kroemer et al. 2009; Galluzzi et al. 2012). The initiator caspases, caspase
8 and caspase 9, are derived from procaspase 8 and procaspase 9, which
will activate the effector caspases, such as caspase 3, and caspase 7
(Sivananthan et al. 2010). The activated effector caspases then cleave a
subset of more than 100 cellular proteins which are important for cell
structure, cellular repair, and cell cycle related proteins (Degterev et al.
2003), causing arrest of vital cellular functions as well as lethal catabolic
reactions (Martins et al. 2011; Cheng et al. 2010; Tadokoro et al. 2010;
Boatright et al. 2003). In mammals, the caspase-dependent apoptosis is
further subcategorized into extrinsic pathway (death receptor pathway)
and intrinsic pathway (mitochondria pathway) depending upon the
source of the stress signals (Fig. 3). The extrinsic pathway is activated by
extrinsic stimuli such as binding of ligands to cell surface death receptors,
which include Fas, tumor necrosis factor receptor, and Trail receptors.
On the other hand, the intrinsic pathway is initiated by diverse cellular
G. Wang
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FIGURE 2. Schematic presentation of the caspase dependent and independent apoptotic pathway. 
FIGURE 3. Schematic presentation of the intrinsic and extrinsic pathways of the caspase dependent
apoptotic pathways. 
4
Dose-Response: An International Journal, Vol. 11 [2014], Iss. 2, Art. 10
https://scholarworks.umass.edu/dose_response/vol11/iss2/10
apoptotic stimuli, such as DNA damage and virus infection, which con-
verge at the mitochondria (Baliga and Kumar 2003). Release of
cytochrome c from the mitochondria to the cytoplasm activates the cas-
pase cascade. Cytosolic cytochrome c (cytoC) associates with apoptosis
protease- activating-factor 1 (Apaf-1) and procaspase 9, generating an
intracellular cell death inducing-complex known as “apoptosome”.
Within the apoptosome, caspase 9 is activated, leading to the cleavage of
procaspase 3 to form the activated caspase 3. The extrinsic and intrinsic
pathway then converge on the caspase 3 and subsequently on other pro-
teases and nucleases that drive the cleavage of chromosome DNA and
other terminal events of apoptosis (Baliga and Kumar 2003; Kroemer et
al. 2007). However, caspase inhibition rarely prevents apoptosis com-
pletely, indicating that there are caspase-independent pathways (Kroemer
et al. 2007; Galluzzi et al. 2012; Mailleux et al. 2007; Cordeiro et al. 2010;
Vandenabeele et al. 2010; Broker et al. 2005). Apoptosis inducing factor
(AIF) and cofilin operate as death-effectors in the complete absence of
caspase activation (Fig. 2) (Patterson et al. 2000; Wabnitz et al. 2010; Lee
et al. 2010). The key regulators of caspase-independent apoptosis are
located on the mitochondria membranes, whose integrity (mitochondri-
al outer membrane permeabilization (MOMP)) is regulated by multiple
proteins and processes, including Bcl-2 family members (Esposti 2010),
BH3-only proteins (Cabon et al. 2012), tumor suppressor protein P53
(Galluzzi et al. 2008a; Galluzzi et al. 2011), Protein kinase Cs (Allen-
Petersen et al. 2010; Paoletti et al. 2010), epigenetic perturbations
(Yelamanchili et al. 2010; Tenedini et al. 2010; Sancho-Pelluz et al. 2010;
Lei et al. 2010; Lanzillotta et al. 2010), and cell cycle perturbations (Fig.
2) (Mitchell et al. 2010).
Autophagy - A physiological hormesis case
The autophagic cell death is initially considered a “Type II” cell death
pathway in that it requires activation of the lysosomal compartment, in
which parts of the cytoplasm are enwrapped in double-memberaned vesi-
cles (called autophagosomes) and degraded by lysosome hydrolases
(Lockshin and Zakeri 2004; Madeo et al. 2010; Criollo et al. 2010).
Autophagy is a normal physiological process that functions to turn over
abnormal proteins and organelles (Lockshin and Zakeri 2004) and is
closely related to apoptosis (Martins et al. 2011; Galluzzi et al. 2008b;
Rufini and Melino 2011; Agostini et al. 2011). Autophagy can counteract
or sustain apoptosis or vise versa and exhibit a typical hormesis pheno-
type. Low levels of autophagy is pro-survival, as it allows for the removal
of the damaged proteins and helps maintain metabolic homeostasis
(Eisenberg-Lerner et al. 2009). Conversely, a high level of autophagy leads
to cell death and cooperates with apoptosis because of the extensive cel-
lular damage (Galluzzi et al. 2008b; Eisenberg-Lerner et al. 2009).
G. Wang
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Autophagy and apoptosis exhibit cross talk on the molecular level, too.
For example, the apoptosis-inducing BH3 proteins have been shown to
liberate Beclin 1 from its interaction with Bcl-2-like proteins, thereby
leading to autophagy (Buttner et al. 2011; Juhasova et al. 2011).
Necrosis -
Necrosis is historically considered a “type III” cell death pathway
(Golstein and Kroemer 2007; Kroemer et al. 2009; Krysko et al. 2008a). It
is originally defined as a type of cell death that lacks the features of apop-
tosis and autophagy (Golstein and Kroemer 2007; Syntichaki and
Tavernarakis 2002; Nicotera and Melino 2004; Chiong et al. 2011). Cells
suffer necrotic cell death when exposed to extreme environmental or
physiological conditions (Syntichaki and Tavernarakis 2002). Necrosis
was often considered chaotic and uncontrolled, leading to local inflam-
mation, and being connected to unwanted cell loss in many types of
human pathologies (Golstein and Kroemer 2007; Festjens et al. 2006;
Yuan 2006). However, recent advances have slowly overturned this grim
prospect and suggested that the occurrence and course of necrosis might
be tightly regulated (Syntichaki and Tavernarakis 2002; Golstein and
Kroemer 2007; Nicotera and Melino 2004). Increasing evidence demon-
strates that regulated necrosis, referred to as necroptosis
(Vanlangenakker et al. 2012; Nicotera and Melino 2004), is not anymore
an isolated observation of a particular cell line or in certain conditions,
but is also recognized as an in vivo cellular defense mechanism against
viral infections and as being critically involved in ischemia-reperfusion
damage(Degterev et al. 2005; Galluzzi et al. 2012; Vanlangenakker et al.
2012). Breakthroughs come from the discovery that the kinase activities
of RIPK1/ RIPK3 are crucial for necroptosis (Degterev et al. 2008; He et
al. 2009; Zhang et al. 2009; Vandenabeele et al. 2010). Despite these
advances, there are still no specific positive biochemical biomarkers for
the in situ detection of necrosis in vitro and in vivo (Vanlangenakker et al.
2012). The release of intracellular proteins such as high-mobility group
box 1 protein (HMGB1) (Scaffidi et al. 2002) and cyclophilin A (CypA)
(Christofferson and Yuan 2010) has been proposed as a candidate necrot-
ic biomarker. However, HMGB1 and CypA can also be passively released
from cells dying by secondary necrosis following apoptosis (Scaffidi et al.
2002) or actively secreted from activated immune cells or cells dying from
pyroptosis, a term introduced to describe necrosis-like cell death that is
dependent on caspase-1 activity (Fink and Cookson 2005). The ratio
between caspase-cleaved cytokeratin-18 released from apoptotic cells and
intact cytokeratin-18 released from cells dying from other causes, includ-
ing necrosis, has also been proposed as a marker to determine qualita-
tively and quantitatively the extent of both types of cell death (Kramer et
al. 2004), but should again be taken with caution (Vanlangenakker et al.
Hormesis for Regenerative Medicine
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2012). So far, the mostly used method to determine necrosis is to com-
bine morphology with immunofluorescence studies (Vanlangenakker et
al. 2012; Krysko et al. 2008a; Krysko et al. 2008b). Necrotic cells typically
exhibit intact extracellular nuclei in electron microscopy images, and are
Tdt-mediated dUTP nick end labeling (TUNEL) positive, but caspase 3
negative in immunofluorescence images (Krysko et al. 2008a; Krysko et al.
2008b; Vanlangenakker et al. 2012; Golstein and Kroemer 2007; Kroemer
et al. 2009).
MECHANISMS OF HORMESIS IN NEURAL CELLS
Hormesis stimulates multiple bioprotective mechanism, including
induction of cytoprotective pathways (such as molecular chaperones),
antioxidative stress, DNA repair, and immune system activation to protect
neural cells from various forms of cell death (Calabrese et al. 2008a;
Calabrese et al. 2008b; Kendig et al. 2010). Here, we will briefly discuss the
induction of anti-apoptotic molecular chaperones and antioxidative
stress proteins by hormesis.
Expression of molecular chaperones (usually called heat shock pro-
teins (Hsps)) is an important intracellular defense mechanism against
stressful conditions (Homma et al. 2007; Wang et al. 2001, 2003, 2004).
Hsps are indispensible for protein homeostasis in normal physiological
conditions (Calabrese et al. 2010; Terasawa et al. 2005; Whitesell and
Lindquist 2005; Trepel et al. 2010). They also serve a vital role of protein
protection and cell protection against cell death during adverse situations
(Arumugam et al. 2006). The importance of Hsps in protection of neural
cells against neurodegenerative diseases is increasingly recognized. It has
been found that levels of Hsp70 and GRP78 are increased in neurons sub-
jected to low level stressors, which serve to protect the neurons against
otherwise lethal levels of oxidative or metabolic stresses (Guo et al. 2001;
Arumugam et al. 2006).
Low level of free radicals generated by mild oxidative stresses can acti-
vate signaling pathways that increase resistance of neurons to more severe
stresses (Otani 2004; Juhaszova et al. 2004). This hormesis mechanism
involves activation of the N-Methyl-D-Aspartate (NMDA) receptor and
brain- derived nerve factor (BDNF) (Marini and Novelli 1991; Marini et
al. 2008; Arumugam et al. 2006). Multiple antioxidative systems are trig-
gered or enhanced in response to mild oxidative stresses, including
antioxidative enzymes, glutathione and proteins involved in stabilization
of mitochondrial membranes (Liu et al. 2002; Arthur et al. 2004).
STEM CELL THERAPY OF NEURODEGENERATIVE DISEASES AND STROKE
Chronic neurodegenerative diseases, such as Alzheimer’s disease and
Parkinson’s disease create a considerable burden to individuals, families,
and the society. In addition, the catastrophic impact of stroke to quality
G. Wang
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of life is severe. Thus, it is of pivotal importance to develop innovative
methods to treat or prevent these diseases. Regenerative medicine has
emerged to be one of the most promising approaches.
Two sets of strategies have been proposed to regenerate cells in order
to repair the damaged brain tissues. The first strategy is through donor
cell transplantation (from either autologous or allogenic cell sources).
Over the last decade, credible data have demonstrated the safety and fea-
sibility of injected stem cells in inducing neural cell regeneration and
functional recovery in animal models of stroke, Parkinson’s disease,
Huntington’s disease, and Alzheimer’s disease (Gogel et al. 2011; Francis
and Wei 2010; Haider and Ashraf 2010; Herrmann et al. 2010; Savitz et al.
2011). Human neural stem cells (HNSCs) transplanted into aged rat
brains differentiated into neural cells and significantly improved the cog-
nitive functions of the animals (Sugaya 2005; Sugaya et al. 2006; Roitberg
et al. 2006; Qu et al. 2001; Winkler 2001). Cells from different sources
have been examined and proved effective, including neural stem cells
(NSC) derived from embryonic stem (ES) cells or induced pluripotent
stem (iPS) cells, and fetal or adult neural stem cells (Zeng et al. 2010;
Gogel et al. 2011; Haider and Ashraf 2010; Wang et al. 2011; Haas et al.
2005; Wang et al. 2009; Theus et al. 2008; Wei et al. 2012; Kelly et al. 2004;
Bliss et al. 2006; Horie et al. 2011). Pluripotent stem cells are no longer
seen as a safe cell sources as its transplantation leads to teratoma forma-
tion (Gogel et al. 2011). Therefore, direct differentiation and purification
of ESCs into defined neural subtypes is preferred.
Another cell source for transplantation is MSCs (Haider and Ashraf
2010; Wang et al. 2009; Wei et al. 2012; Geng 2003; Toma et al. 2002).
MSCs can be derived from a variety of tissues such as bone marrow and
cord blood. As they seem to penetrate the blood brain barrier, no invasive
intracerebral surgery is required and instead a peripheral infusion can be
performed to deliver these cells to the brain. However, questions still
remain that how many of these cells travel to the brain and to what extent
they differentiate into different neural cell types (Gogel et al. 2011).
The second strategy is to enhance endogenous neurogenesis and thus
boost endogenous repair mechanisms of the brain (Savitz et al. 2011).
Much evidence has been found that the brain is capable of regenerating
neurons after their maturation (Sugaya 2005; Sugaya et al. 2006; Qu et al.
2001; Eriksson et al. 1998; Allen et al. 2001; Aimone et al. 2006; Jagasia et
al. 2006), and stroke can stimulate neurogenesis migration of neural
stem/progenitor cells into damaged brain region (Greenberg 2007;
Wiltrout et al. 2007; Chopp et al. 2007; Liu et al. 2007). But the extent to
which this neurogenesis can replace lost neural cells and contribute to
functional improvement is not clear (Gogel et al. 2011). It is believed that
protection, and/or enhancement of proliferation, of the endogenously-
newly-generated neural cells by mechanisms of hormesis could be a viable
Hormesis for Regenerative Medicine
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approach, by which a sufficient amount of cells generated to promote the
functional recovery of the patients (Gogel et al. 2011; Hess and
Borlongan 2008; Marini et al. 2008).
HORMESIS FOR REGENERATIVE MEDICINE
Hormesis has been proven to reduce cell death and aid in survival in
both of these two scenarios. For the strategy to transplant donor stem
cells, the following hormetic methods have been found to enhance stem
cell survival and/or mobilization: mild hypoxia (Lian and Tse 2010;
Kamota et al. 2009; Wei et al. 2012; Theus et al. 2008), the antibiotic
minocycline (Sakata et al. 2012), an endogenous peptide apelin (Zeng et
al. 2012; Wang et al. 2012), and others (Wisel et al. 2009; Salloum et al.
2012; Hoke et al. 2012; Kwon et al. 2008). Our group has found that treat-
ment with a low dose Hsp90 inhibitor 17-N-Allylamino-17-demethoxygel-
danamycin (17-AAG) protects NPCs from naturally-occurring and stress
induced apoptosis, with a typical reversed U-shaped hormetic dose-
response relationship (Wang et al. 2011) (Fig. 4). Mechanistically, low
dose 17-AAG activates the stress response pathway, MAP kinase pathway,
and PI3K/Akt pathways. This is of profound clinical relevance, since
many Hsp90 inhibitors, including 17-AAG, are in clinical trials against
multiple malignancies, and have overcome the toxicity and solubility
problems (Kummar et al. 2010; Trepel et al. 2010; Waza et al. 2005, 2006).
Hormesis is also a promising strategy to protect endogenous neu-
rons and enhance endogenous neurogenesis (Gogel et al. 2011; Marini
et al. 2008). One example of hormetic protection of neurons is gluta-
mate, the major excitatory amino acid that mediates physiological exci-
tation. Glutamate is involved in both acute and chronic neurodegener-
ative disorders (Dobrek and Thor 2011; Lau and Tymianski 2010). High
G. Wang
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level activation of the ionotrophic glutamate receptor leads to neuronal
cell death. However, low level activation of glutamate receptors exerts
neuron protection (Marini et al. 2008; Marini and Novelli 1991; Jonas et
al. 2001; Calabrese et al. 2007). Another interesting proposal is to utilize
the cytoprotective effect of autophagy to protect neurons from the hos-
tile disease environment. Since mild autophagy can lead to the removal
of damaged and potentially dangerous mitochondria, it increases the
threshold for cell death induction by MOMP-inducing agents or stres-
sors (Blagosklonny 2010; Bennett et al. 2010; Deng et al. 2010; Degli
Esposti et al. 2011). Thus mild autophagy may be a promising strategy
to reduce the propensity of neurons to undergo apoptosis or necrosis
(Martins et al. 2011).
We have mentioned that chronic or acute brain damage induces neu-
rogenesis, although their beneficial effect is not clear. Supporting these
newly generated cells by infusion of neurotrophic factors or other meas-
ures that enhance neurogenesis, or boost the survival of the newly gen-
erated stem/progenitor cells, could help rebuild a sufficient amount of
the lost circuitry, hence improving functional recovery of the patients
(Gogel et al. 2011; Hess and Borlongan 2008; Li et al. 2008b; Misumi et al.
2008). Many types of stimulation methods have been tested and proven
beneficial, including ischemia preconditioning, exercise, and peripheral
stimulation (Li et al. 2008b; Andoh et al. 2002; Dawson 2002). Our group
found that injection of 17-AAG increased the number of newly generated
neural cells, in both the subventricular zone and the subgranular zone,
by about 60%, accompanied by triggering phosphorylation of cytopro-
tective kinases Akt and GSK-3b in the brain (Wang et al. 2011). .
CONCLUSIONS AND PERSPECTIVES
Stem cells delivered into the brain (or newly regenerated) can sup-
port a certain amount of neural function by secreting trophic factor vas-
cular endothelial growth factor (Bliss et al. 2006; Horie et al. 2011).
However, the injected cells do not infiltrate and survive the damaged
region, let alone reconstruction of the lost neural circuit, undermining
the idea and full potential of regenerative medicine (Bliss et al. 2006;
Kelly et al. 2004; Horie et al. 2011). Therefore it is vital to optimize the
treatment procedure so that the newly generated (or transplanted) cells
survive and correctly differentiate into desired cell types in the brain.
Many studies have found that hormesis potentiates stem cells to a state in
which they can endure much harsher environment and improve func-
tional recovery in animal models of neurodegenerative disease. Hence it
is rational to promote the combination of stem cell therapy with horme-
sis to achieve a more desirable outcome, and encouraging more research
in the related field.
Hormesis for Regenerative Medicine
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Cell death is a very complex process and our understanding of its
mechanism is advancing in an unprecedented pace. More importantly,
since the cell death patterns and their underlying molecular mechanism
may vary in different diseases and even in different progression stages of
the same disease, it is essential to design a suitable and optimum hormet-
ic strategy that is tailored to the individual patient. Thus it calls for com-
prehensive approaches to achieve protection of the newly generated (or
transplanted) cells so that they are more suited for regenerative medi-
cine.
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